Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

147
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
147
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

387
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
387
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

276
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
276
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

88
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
88
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

938
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
938
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

246
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
246

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The relevance of phenotypic definition in treatment resistant forms of major depressive disorder: a narrative review.

Frontiers in pharmacology·2026
Same author

Burden of rare genetic variants in genes associated with cancer among Malawian cervical cancer patients.

African journal of laboratory medicine·2026
Same author

Integrating Genetic Variants and Expression Profiles of Pharmacogenes to Investigate Resistance to Antidepressant Treatment.

Medicina (Kaunas, Lithuania)·2026
Same author

DNA methylation signatures associated with bipolar disorder in peripheral blood improve prediction models.

EBioMedicine·2026
Same author

Genetic Variation in <i>CYP2B6</i>, <i>UGT1A4</i> and Sulfotransferases Is Associated with Disease-Free Survival in South African Breast Cancer Patients Treated with Tamoxifen.

Journal of personalized medicine·2026
Same author

The effect of childhood trauma on the severity of depressive symptoms and drug resistance in major depressive disorder - results from the international PROMPT study.

Journal of affective disorders·2026

Related Experiment Video

Updated: Mar 16, 2026

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
07:37

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Published on: January 9, 2020

10.1K

Minimum information required for a DMET experiment reporting.

Judit Kumuthini1, Mamana Mbiyavanga1, Emile R Chimusa1,2

  • 1Centre for Proteomic & Genomic Research, Cape Town, South Africa.

Pharmacogenomics
|August 23, 2016
PubMed
Summary
This summary is machine-generated.

New Minimum Information required for a DMET Experiment (MIDE) reporting guidelines standardize pharmacogenomics data. These guidelines and XML schema facilitate data sharing and reanalysis for the scientific community.

Keywords:
DMETbioinformaticsminimum information requirement guidelinespersonalized genomicspersonalized medicinepharmacogenomicsstandardization

More Related Videos

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

43.0K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.3K

Related Experiment Videos

Last Updated: Mar 16, 2026

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
07:37

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Published on: January 9, 2020

10.1K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

43.0K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.3K

Area of Science:

  • Pharmacogenomics
  • Bioinformatics
  • Data Science

Background:

  • Effective interpretation, sharing, and reproducibility of pharmacogenomics data are crucial for advancing research.
  • Current reporting practices lack standardization, hindering data integration and analysis.

Purpose of the Study:

  • To establish standardized reporting guidelines for pharmacogenomics experiments.
  • To facilitate the submission of pharmacogenomics data to public omic databases.

Main Methods:

  • Development of the Minimum Information required for a DMET Experiment (MIDE) reporting guidelines.
  • Creation of an XML schema for standardized data representation.

Main Results:

  • MIDE provides comprehensive reporting guidelines for DMET experiments.
  • The MIDE guidelines specify information required for reporting, data storage, and data sharing.

Conclusions:

  • The MIDE guidelines and XML schema will enhance the sharing, dissemination, and reanalysis of pharmacogenomics datasets.
  • Standardized reporting will improve transparency and accessibility of pharmacogenomics data for the scientific community.